These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 8557985

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
    Hayun M, Saida H, Albeck M, Peled A, Haran-Ghera N, Sredni B.
    Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
    [Abstract] [Full Text] [Related]

  • 9. Antibabesial effect of the immunomodulator AS101 in mice: role of increased production of nitric oxide.
    Rosenblatt-Bin H, Klein A, Sredni B.
    Parasite Immunol; 1996 Jun; 18(6):297-306. PubMed ID: 9229382
    [Abstract] [Full Text] [Related]

  • 10. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate.
    Kalechman Y, Zuloff A, Albeck M, Strassmann G, Sredni B.
    Blood; 1995 Mar 15; 85(6):1555-61. PubMed ID: 7888674
    [Abstract] [Full Text] [Related]

  • 11. The protective role of ammonium trichloro(dioxoethylene-O,O')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action.
    Kalechman Y, Shani A, Sotnik-Barkai I, Albeck M, Sredni B.
    Cancer Res; 1993 Dec 15; 53(24):5962-9. PubMed ID: 8261410
    [Abstract] [Full Text] [Related]

  • 12. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101.
    Frei GM, Kremer M, Hanschmann KM, Krause S, Albeck M, Sredni B, Schnierle BS.
    Br J Dermatol; 2008 Mar 15; 158(3):578-86. PubMed ID: 18241275
    [Abstract] [Full Text] [Related]

  • 13. Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective properties.
    Kalechman Y, Shani A, Albeck M, Sredni B.
    Immunopharmacology; 1995 Mar 15; 29(2):149-58. PubMed ID: 7539780
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels.
    Kalechman Y, Gafter U, Da JP, Albeck M, Alarcon-Segovia D, Sredni B.
    J Immunol; 1997 Sep 15; 159(6):2658-67. PubMed ID: 9300685
    [Abstract] [Full Text] [Related]

  • 19. Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake.
    Frei GM, Lebenthal I, Albeck M, Albeck A, Sredni B.
    Biochem Pharmacol; 2007 Sep 01; 74(5):712-22. PubMed ID: 17632085
    [Abstract] [Full Text] [Related]

  • 20. Radioprotective effects of the immunomodulator AS101.
    Kalechman Y, Albeck M, Oron M, Sobelman D, Gurwith M, Seghal SN, Sredni B.
    J Immunol; 1990 Sep 01; 145(5):1512-7. PubMed ID: 2384668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.